Clinical Study to Evaluate Remineralization Using an in Situ Model. (REMINSITU)
Clinical Study to Evaluate Enamel Remineralization Using Three Dentifrices in an in Situ Model.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
This Phase III, randomized, single-center, triple-blind, crossover clinical study will evaluate the remineralization efficacy of three dentifrices on artificially induced initial enamel caries lesions. The research will involve 30 healthy participants aged 18 to 70 years who meet strict inclusion criteria. The experimental design will utilize an in situ model where participants will wear custom-made removable mandibular intraoral appliances containing four human enamel blocks with pre-formed artificial caries lesions. These lesions will be created laboratory-side using an acidified gel demineralization system before the blocks are mounted into the appliances.
The study will follow a nine-week timeline, divided into three 14-day experimental phases separated by 7-day washout periods to eliminate carryover effects, totaling 8 visits. During the treatment phases, subjects will be randomly assigned to a sequence of three test products: a test dentifrice with 750 ppm MFP, a positive control with 1450 ppm MFP, and a fluoride-free negative control. Each participant will receive a soft-bristle toothbrush and the assigned toothpastes.
The primary outcome will be the change in integrated mineral loss measured by transverse microradiography (TMR). Baseline mineral loss will be established from a slice of each block before intraoral exposure and compared to post-treatment analysis of the adjacent tissue. Secondary outcomes will include changes in lesion depth and fluorescence loss parameters assessed via Quantitative Light-induced Fluorescence (QLF).
Statistical analysis will be performed using a linear mixed-effects ANCOVA model to confirm the hypothesis that the 750 ppm MFP dentifrice promotes significantly greater remineralization than the negative control, with effects lower than or comparable to the high-fluoride positive control.
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 3단계
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Fábio Correia Sampaio, PhD
- 전화번호: +55 83 999821111
- 이메일: fabio.correia.sampaio@academico.ufpb.br
연구 장소
-
-
Paraíba
-
João Pessoa, Paraíba, 브라질, 58.051-900
- Federal University of Paraíba
-
연락하다:
- Fábio Correia Sampaio, PhD
- 전화번호: +55 83 99982-1111
- 이메일: fabio.correia.sampaio@academico.ufpb.br
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
설명
Inclusion Criteria:
- Males and females, between 18-70 years of age (inclusive);
- Informed Consent Form signed and availability for the duration of the study;
- Good general health (absence of any condition that, in the opinion of the Principal Investigator, might constitute a risk to the subject while participating in the study. Examples include heart problems, valve/hip replacements, etc);
- Willingness to provide information related to their medical history;
- Minimum of 20 uncrowned permanent natural teeth (excluding third molars);
- Normal salivary flow;
- Willingness to wear an intra-oral appliance all day as instructed except when eating and drinking.
Exclusion Criteria:
- Oral pathology, chronic disease, or a history of allergy to testing products;
- Subject using anticonvulsants, antihistamines, antidepressants, sedatives, tranquilizers, anti-inflammatory medication or daily analgesics within one month prior to the start of the study or scheduled to start such intake during the course of the study;
- Subject participating in any other clinical study;
- Subject pregnant or breastfeeding;
- Subject allergic to oral care products, personal care consumer products, or their ingredients;
- Extended use of antibiotics or therapeutic mouthwash any time during the three months prior to entry into the study;
- A medical history reporting that the subject has a current systemic or autoimmune disease, such as diabetes, lupus, etc.;
- Ongoing use of medications known to affect the gingival tissues (i.e. calcium channel blockers, phenytoin, cyclosporine);
- Advanced periodontal disease (purulent exudate, tooth mobility, and/or extensive loss of periodontal attachment or alveolar bone). Pocket depth equal or greater than 4 mm;
- Five or more decayed, untreated dental sites (cavities);
- Current smokers and subjects with a history of alcohol or drug abuse;
- Dental work prevents wearing of the appliance or a reported need to wear a night guard.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 다른
- 할당: 무작위
- 중재 모델: 크로스오버 할당
- 마스킹: 네 배로
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: Test Group
Subjects will brush using a fluoride toothpaste containing 750 ppm MFP in a Dical base and a soft bristle toothbrush
|
시중에 판매되는 성인용 부드러운 강모 칫솔
Subjects will brush using a fluoride toothpaste containing 750 ppm MFP in a Dical base and a soft bristle toothbrush for 14 days
|
|
활성 비교기: Positive Control Group
Subjects will brush using a fluoride toothpaste containing 1450 ppm MFP in a Dical base and a soft bristle toothbrush
|
시중에 판매되는 성인용 부드러운 강모 칫솔
Subjects will brush using a fluoride toothpaste containing 1450 ppm MFP in a Dical base and a soft bristle toothbrush for 14 days
|
|
가짜 비교기: Negative Control Group
Subjects will brush using a fluoride-free toothpaste in a Dical base and a soft bristle toothbrush
|
시중에 판매되는 성인용 부드러운 강모 칫솔
Subjects will brush using a fluoride-free toothpaste in a Dical base and a soft bristle toothbrush for 14 days
|
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change in integrated mineral loss (Δz)
기간: 9 weeks
|
Integrated mineral loss (Δz) will be assessed by transverse microradiography (TMR).
This outcome will evaluate the change from the baseline demineralized state (Δz0) to the post-treatment state (Δz1) to quantify the net mineral gain or loss.
|
9 weeks
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change in lesion depth
기간: 9 weeks
|
Post-treatments lesion depth (LD) will be assessed by TMR.
For each experimental phase, post-treatment values will be compared with corresponding baseline measurements to determine the extent of remineralization.
|
9 weeks
|
|
Change from Baseline in Fluorescence Loss
기간: 9 weeks
|
Fluorescence loss ΔF, will be assessed by quantitative light-induced fluorescence (QLF) to measure the percentage loss of fluorescence intensity.
The change will be calculated by comparing post-treatment values at 9 weeks with baseline measurements.
|
9 weeks
|
|
Change from Baseline in Maximum Fluorescence Loss ΔFmax at 9 Weeks
기간: 9 weeks
|
Maximum fluorescence loss ΔFmax at the deepest point of the lesion will be assessed by quantitative light-induced fluorescence (QLF).
The change will be calculated by comparing post-treatment values at 9 weeks with baseline measurements.
|
9 weeks
|
|
Change from Baseline in Fluorescence Loss Volume (ΔQ) at 9 Weeks
기간: 9 weeks
|
Fluorescence loss volume (ΔQ) will be assessed by quantitative light-induced fluorescence (QLF).
The change will be calculated by comparing post-treatment values at 9 weeks with baseline measurements.
|
9 weeks
|
공동 작업자 및 조사자
협력자
협력자
수사관
수사관
- 수석 연구원: Fábio Correia Sampaio, PhD, Federal University of Paraíba
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
기타 연구 ID 번호
- CRO-2026-02-REMIN-BZ-CB
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .